Reboxetine, does it offer advantages over SSRIs?

Third-generation antidepressants:
do they offer advantages over the SSRIs?

Olver JS, Burrows GD, Norman TR.

Department of Psychiatry,
University of Melbourne,
Austin & Repatriation Medical Centre,
West Heidelberg, Victoria, Australia.
CNS Drugs 2001;15(12):941-54

ABSTRACT

Third-generation antidepressants are a group of antidepressant agents of variable action, not confined to serotonin reuptake inhibition. These agents include venlafaxine, reboxetine, nefazodone and mirtazapine. Claims have been made for these agents in terms of improved efficacy, faster speed of onset of effect and greater safety in the treatment of depression compared with previous medications, such as the selective serotonin reuptake inhibitors (SSRIs). This article reviews the evidence for these improvements. Thirty active comparator studies were reviewed involving the third-generation antidepressant agents. While there were isolated reports of improvements over comparator agents for venlafaxine, reboxetine and mirtazepine, there were no convincing differences between third-generation agents and comparators in terms of overall efficacy, relapse prevention and speed of onset. The third-generation antidepressants were, however, of equivalent safety to SSRIs and maintained improvements in safety over first-generation agents.

Tianeptine | Moclobemide | Picamilon | cataract | stroke | diabetes
Home | Order

           Reboxetine  research / abstracts

  1. Reboxetine role in antidepressant therapy
2. Reboxetine efficacy and tolerability
  3. Reboxetine clinical pharmacologic profile
4. Reboxetine Inhibiting noradrenaline and serotonin reuptake
5. Reboxetine and depression in the elderly
6. Reboxetine with severe major depressive disorder
7. Reboxetine clinical efficacy in major depression
8. Reboxetine tolerability and safety for major depression
9. Reboxetine comparison with fluoxetine
10. Reboxetine versus fluoxetine, impact on social functioning
11. Reboxetine  versus fluoxetine, differential effects
12. Reboxetine prevents relapse in major depression
13. Reboxetine efficacy compared with imipramine
14. Noradrenaline reuptake inhibition
15. Antidepressants noradrenergic versus serotonergic
16. Reboxetine in the treatment of bulimia
17. Reboxetine hemodynamic effects in healthy males
18. Reboxetine effects of antidepressant therapy
19. Reboxetine place in antidepressant therapy
20. Reboxetine stimulant effects in patients with narcolepsy
21. Reboxetine selective noradrenaline reuptake inhibitor (NARI)
   Reboxetine manufacturer's product insert

HOME to order

Hit Counter